For many, a bill for more than a quarter million dollars is nothing to scoff at-but while treating those with cancer, these costs are all too common.
For many, a bill for more than a quarter million dollars is nothing to scoff at—but while treating those with cancer, these costs are all too common. Cancer drugs like Avastin, which is used as a second-line treatment after initial treatment has failed, can extend the median overall survival rate of a patient by 42 days at the cost of $5000 a month. If you extended that 42 days’ survival to a year, the regimen can average over $300,000.
“Now, that’s essentially the cost of the bare-bones drug,” Dr Leonard Saltz, an oncologist from Memorial Sloan-Kettering Cancer Center, said in a recent article. “It’s parts, not labor. No money for doctors; no money for nurses; no money for pharmacists; no money for real estate, heat, and lights; no money for the needles, the IV tubing, the IV fluids, the anti-nausea medicines, the other chemotherapies that are given, because Avastin doesn’t do anything by itself. It has to be given with other drugs … I want to emphasize it’s not that we can have a year of life saved for $303,000. That’s probably less than half of what the actual cost would be when you factor in everything.”
Newly FDA-approved drugs such as Zaltrap are likely to fall under even more astronomical financial constraints. Dr Saltz reported that Sanofi and Regeneron Pharmaceuticals, who manufacture the drug Zaltrap, said the new drug would cost almost $11,000 a month. The price of a 6-week life extension would be as high as $75,000. It’s obvious that practitioners like Saltz have difficulty rationalizing the costs of these new drugs when comparatively they provide the same benefits as existing treatments. However, if a doctor considers the actual value of a costly drug, they risk being accused of rationing healthcare.
“There is a number in people’s minds,” Saltz adds. “If you say to people, ‘I have a drug that extends life by one day at a billion dollars; shouldn’t we as a society pay for it?,’ I’m pretty confident most people would say no. If I say, ‘I have a drug that extends life by three years at a cost of $1.50,’ I’m pretty confident everybody would say, ‘Of course!’ Somewhere in there is a number, a tipping point, where we say, ‘No, we can’t.’ Right now, we’re unwilling as a society to explore where that point is. And I would argue that we have to. Wherever it may be, we have to find it.”
Around the Web
The Cost of Living [NY Magazine]
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
More than 5 years after the American Society of Clinical Oncology warned of emerging disparities in precision medicine, efforts by community practices to embrace technology, form partnerships, and use data show how patients can gain access to personalized approaches. But challenges remain, especially for those covered by Medicaid.
Read More